D-1842-2019 Class III Terminated

Recalled by Aurobindo Pharma USA Inc. — East Windsor, NJ

FDA drug recall D-1842-2019 was initiated by Aurobindo Pharma USA Inc. on Jul 29, 2019 and is designated Class III. Reason for recall: Labeling; Incorrect or Missing Lot and/or Exp Date; some bottles labeled with lot number 05318054B instead of 05318034B The recall status is terminated (terminated Oct 28, 2021). Affected quantity: 2,352/1000 count bottles.

Recall details

Product Type
Drugs
Report Date
Sep 4, 2019
Initiation Date
Jul 29, 2019
Termination Date
Oct 28, 2021
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
2,352/1000 count bottles

Product description

Simvastatin Tablets, USP 40 mg. Rx Only 1000 Count Bottles Manufactured by: Aurolife Pharma LLC Dayton NJ 08810 Manufactured for: Aurobindo Pharma USA, Inc. Dayton, NJ 08810 NDC 65862-053-99

Reason for recall

Labeling; Incorrect or Missing Lot and/or Exp Date; some bottles labeled with lot number 05318054B instead of 05318034B

Distribution pattern

Product was distributed nationwide by three major distributors who may have further distributed the product.

Code information

05318054B, exp 3/2021

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1842-2019
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-1842-2019. Report a data issue: hello@regdatalab.com.